Navigation Links
Vanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:12/3/2013

WASHINGTON, Dec. 3, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corporate presentation at the 25th Annual Piper Jaffray Healthcare Conference in New York City on Wednesday, December 4, 2013 at 11:30 a.m. Eastern Time.

The presentation at the Piper Jaffray Healthcare Conference will be available live on Vanda's corporate website, where it also will be archived for 30 days.  To access the presentation, go to Vanda's website at www.vandapharma.com and click on the Presentations tab on the Investor Relations page.  Please connect to the website several minutes prior to the start of the live presentation.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Vanda Pharmaceuticals Reports First Quarter 2013 Results
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Calif. , Aug. 15, 2017 After spending the ... and support with crowdsourced data collection, GeneFo now offers this platform ... in aligning and amplifying support, adherence, and data collection vis a ... medical foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Pittcon is pleased to once ... scientific instruments. This year’s symposium, organized by the Pittcon 2018 program chair, Annette ... Applications.” This dynamic presentation will discuss novel ionization processes, high throughput IMS-MS technologies, ...
(Date:8/15/2017)... ... August 15, 2017 , ... The Conference Forum and ... programming through a series of upcoming panels and events. The partnership culminates with the ... Roosevelt Hotel in New York City. , “With our experience in producing the Immuno-Oncology ...
(Date:8/14/2017)... Yorba Linda, Ca (PRWEB) , ... August 14, ... ... allocated for poorly characterized and performing antibodies. Key researchers in the antibody community ... ensure proper characterization and consistency for antibodies in the laboratory. , ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
Breaking Biology News(10 mins):